LUNDBECK ANNOUNCES HEADLINE RESULTS FROM PHASE IV THRIVE TRIAL EVALUATING VYEPTI® (EPTINEZUMAB) FOLLOWING INADEQUATE RESPONSE TO PRIOR CGRP-TARGETING PREVENTIVE THERAPY

Reuters · 1d ago

Please log in to view news